The investigation centers on whether leadership at the NASDAQ-listed biotech firm prioritized personal interests over the obligations owed to its stakeholders. Justin Kuehn, the attorney leading the inquiry, is inviting long-term stockholders to come forward to discuss the potential for litigation. The firm has stated that consultations for affected investors are free of charge, with Kuehn Law covering all associated case costs.

Investors are urged to act quickly, as legal windows to enforce shareholder rights are often constrained by strict timelines. Those interested in the probe can reach the firm via email at jkuehn@kuehnlaw.com or by phone at (833) 672-0814. This action is classified as attorney advertising, and the firm notes that past legal outcomes do not serve as a guarantee of success in this specific matter.